Thermo Fisher Scientific Inc. $TMO Shares Purchased by USS Investment Management Ltd

Key Points

• USS Investment Management Ltd increased its Thermo Fisher Scientific stake by 3.5% in the first quarter, bringing holdings to 65,801 shares valued at about $32.4 million.
• Thermo Fisher reported strong quarterly results, with EPS of $5.44 beating estimates and revenue of $11.01 billion topping expectations; revenue also rose 6.2% year over year.
• The company declared a quarterly dividend of $0.47 per share payable July 15, while analysts currently rate the stock a Moderate Buy with a consensus target price of $605.09.

USS Investment Management Ltd raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 65,801 shares of the medical research company's stock after buying an additional 2,208 shares during the period. USS Investment Management Ltd's holdings in Thermo Fisher Scientific were worth $32,362,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. J. Stern & Co. LLP raised its position in shares of Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock valued at $18,258,082,000 after purchasing an additional 31,455,105 shares in the last quarter. Norges Bank bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $3,072,744,000. Auto Owners Insurance Co raised its holdings in Thermo Fisher Scientific by 57,845.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company's stock valued at $1,406,844,000 after acquiring an additional 2,423,706 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Thermo Fisher Scientific by 2,183.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,328,845 shares of the medical research company's stock valued at $770,000,000 after acquiring an additional 1,270,643 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in Thermo Fisher Scientific by 88.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company's stock worth $1,309,292,000 after acquiring an additional 1,270,191 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Down 1.2%

NYSE:TMO opened at $500.36 on Wednesday. Thermo Fisher Scientific Inc. has a 12-month low of $403.36 and a 12-month high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The business has a 50 day simple moving average of $473.35 and a 200 day simple moving average of $518.92. The firm has a market capitalization of $185.94 billion, a P/E ratio of 27.51, a P/E/G ratio of 2.24 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. The company had revenue of $11.01 billion for the quarter, compared to analysts' expectations of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm's quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the business posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific's payout ratio is presently 10.34%.

Analyst Ratings Changes

Several equities analysts have recently commented on TMO shares. Stifel Nicolaus reduced their price target on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating on the stock in a research report on Friday, April 24th. Piper Sandler initiated coverage on Thermo Fisher Scientific in a research note on Thursday, June 11th. They set a "neutral" rating and a $510.00 price objective on the stock. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a research report on Friday, May 8th. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a report on Friday. They issued a "market perform" rating and a $520.00 price target for the company. Finally, Wolfe Research began coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $605.09.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.